Synapse

← JHEP Reports

Papers in JHEP Reports

Page 9 · newest first

  1. Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosisJHEP Reports · 2025
  2. Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancerJHEP Reports · 2025
  3. Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activityJHEP Reports · 2025
  4. Deep learning can predict cardiovascular events from liver imagingJHEP Reports · 2025
  5. Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinomaJHEP Reports · 2025
  6. Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidatesJHEP Reports · 2025
  7. Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidenceJHEP Reports · 2025
  8. Single-cell analysis of mature hepatocytes reveals an IRF1-driven restriction of HDV infectionJHEP Reports · 2025
  9. C/EBPβ–VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLDJHEP Reports · 2025
  10. ECM1 expression in chronic liver disease: Regulation by EGF/STAT1 and IFNγ/NRF2 signallingJHEP Reports · 2025
  11. Antifibrotic therapies for metabolic dysfunction-associated steatotic liver diseaseJHEP Reports · 2025
  12. The association between childhood obesity and major adverse liver outcomes in adolescence and young adulthoodJHEP Reports · 2025
  13. Temporal dichotomy of neutrophil function in acute liver injury and repairJHEP Reports · 2025
  14. Regional variations and trends in liver transplantation practices across EuropeJHEP Reports · 2025
  15. Identification of pediatric MASLD using insulin resistance indicesJHEP Reports · 2025
  16. DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroidsJHEP Reports · 2025
  17. Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinomaJHEP Reports · 2025
  18. Inflammation in MASLD progression and cancerSHILAP Revista de lepidopterología · 2025
  19. The dual role of TIGIT in regulatory and effector T cells in chronic liver diseaseSHILAP Revista de lepidopterología · 2025
  20. Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLDJHEP Reports · 2025
  21. Pediatric to adult care transfer in rare liver diseases: Recommendations based on insights from a European omnistakeholder eventSHILAP Revista de lepidopterología · 2025
  22. Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infectionJHEP Reports · 2025
  23. p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitisJHEP Reports · 2025
  24. Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisJHEP Reports · 2025
  25. EASL postgraduate course report: Vascular biology in chronic liver disease and clinical management implicationsJHEP Reports · 2025
  26. Deep learning empowered gadolinium-free contrast-enhanced abbreviated MRI for diagnosing hepatocellular carcinomaJHEP Reports · 2025
  27. Ischemia-free liver transplantation improves long-term outcomes in a 5-year follow-up studyJHEP Reports · 2025
  28. Regulatory T cell therapy in autoimmune liver disease and transplantationJHEP Reports · 2025
  29. Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survivalJHEP Reports · 2025
  30. Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort studySHILAP Revista de lepidopterología · 2025
  31. Proinflammatory macrophages release CXCL5 to regulate T cell function and limit effects of αPD-1 in steatosis-driven liver cancerJHEP Reports · 2025
  32. Sex-based disparities in liver transplantation: Evidence from a nationwide Italian cohortJHEP Reports · 2025
  33. Macrophage-derived IL-15 imprints peritoneal TRM-like CD8 T cells in cirrhosis and spontaneous bacterial peritonitisJHEP Reports · 2025
  34. Lipidomics-based plasma signature of alcohol-related hepatitis linked to short-term mortalityJHEP Reports · 2025
  35. A novel in vitro system for simultaneous infections with hepatitis B, C, D and E virusesJHEP Reports · 2025
  36. Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-responseJHEP Reports · 2025
  37. Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysisJHEP Reports · 2025
  38. Thyroid dysfunction in MASLD: Results of a nationwide studyJHEP Reports · 2025
  39. Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatmentJHEP Reports · 2025
  40. Towards precision medicine strategies using plasma proteomic profiling for suspected gallbladder cancer: A pilot studyJHEP Reports · 2025
  41. Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLDSHILAP Revista de lepidopterología · 2025
  42. Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCJHEP Reports · 2025
  43. AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomesJHEP Reports · 2025
  44. Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinomaJHEP Reports · 2025
  45. Multicenter evaluation of abbreviated MRI and ultrasound for detecting early-stage hepatocellular carcinomaJHEP Reports · 2025
  46. Associations between fruit and vegetable consumption and HCC occurrence in patients with cirrhosisJHEP Reports · 2025
  47. Liver fibrosis progression analyzed with AI predicts renal declineJHEP Reports · 2025
  48. Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trialJHEP Reports · 2025
  49. Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studiesJHEP Reports · 2025
  50. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trialsJHEP Reports · 2025